Jon Miller: Hey, guys. Thanks for taking my question and congrats on all the recent progress. The Provention deal included warrants. I know you’re not talking much about the acquisition, but did you exercise as warrants and own prevention stock. And I also noticed that change of control looks like a payment in their filings earlier? Do you have any view on that at this point? And maybe since I know Scott, you said you wouldn’t want to talk about that much. Given that TAMARACK is now no longer controlled, I know you were going to have to go back to the Phase 3 anyway, but is your timing getting into the Phase 3 portion at all delayed by removing the control arm in Phase 2? And how should we think about moving into potentially pivotal cohorts there?
Scott Koenig: So, let me answer that first and then I’ll let Jim address the TZIELD story. Actually as we noted early in the call, we already have four countries and we expect many of these other countries to come on. The sites that are already opened in TAMARACK will continue to enroll patients and any patients that are on control arms will be just switched to an active arm So, really there is no delay. In fact, we believe that by going this route and now adding on additional sites with this amendment, we should be able to enroll the study, as well as getting readout much faster than we would have done with the controlled Phase 2. So, right now we’re still €“ given a lot of sites have to come on, we still need to get regulatory approval in some of the countries, which we expect to occur imminently. We think that we’re still targeting in the second half of 2024 to have clinical readouts here.
Jim Karrels: And Jon, thanks for the question about Provention. With regards to the warrants, we disclosed that we exercised those back in 2019 and we sold those shares, I think we averaged about $12 a share, which at the time seemed quite good. And then with regard to the other question, the Sanofi transaction, obviously, we have the ability to receive regulatory milestones from Provention, as well as certain additional consideration for rights that they grant with respect to the product and we are evaluating and we expect to continue to evaluate the details of the pending Sanofi Provention transactions in that very context.
Jon Miller: Fair enough. But Scott, I was trying to ask about the Phase 3 portion of TAMARACK around Phase 2. I understand that you’re trying to help enrollment along for Phase 2. But does having €“ just dropping the Phase 3 portion now delay your ability to get that going later?
Scott Koenig: I don’t think so. I mean, we’ll have to see as we go forward anticipate. Remember, we’ll get real time data on the Phase 2 study. So, we have the ability to prep what we would see in terms of the Phase 3. And the assumption is that the majority of sites that we would have in the Phase 2 would continue on the Phase 3. And in any case, we would have had to discuss with the FDA what the appropriate control was at that time given the changing landscape. So, ultimately, I think we will have enough lead time to not lose the ability to implement the Phase 3 in a similar timeframe.
Jon Miller: All right. Thanks so much.
Scott Koenig: Thank you.
Operator: Thank you. Our next question comes from Stephen Willey with Stifel. You may proceed.
Stephen Willey: Yes, thanks for taking the question. So, maybe just a point of clarification on the proposed Phase 2 or lorigerlimab trial. So, can these patients have seen docetaxel in the castration sensitive setting or is this a truly chemo-naive patient population?
